Molnupiravir

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instanceOf small molecule
antiviral drug
gptkbp:administeredBy capsule
gptkbp:approvedBy gptkb:India
gptkb:Japan
gptkb:United_Kingdom
gptkb:United_States
2021
gptkbp:ATCCode J05AX27
gptkbp:bioavailability high
gptkbp:brand gptkb:Lagevrio
gptkbp:CASNumber 2349386-89-4
gptkbp:chemicalClass antiviral drug
gptkbp:chemicalFormula nucleoside analog prodrug
gptkbp:clinicalTrialPhase Phase 3
gptkbp:contraindication pregnancy
gptkbp:developedBy gptkb:Emory_University
gptkb:Merck_&_Co.
gptkb:Ridgeback_Biotherapeutics
gptkbp:eliminatedIn renal
gptkbp:form oral capsule
gptkbp:halfLife 3.3 hours
gptkbp:hasMolecularFormula C13H19N3O7
https://www.w3.org/2000/01/rdf-schema#label Molnupiravir
gptkbp:indication mild to moderate COVID-19
patients at risk of severe COVID-19
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction RNA-dependent RNA polymerase inhibitor
gptkbp:molecularWeight 329.31 g/mol
gptkbp:notRecommendedFor children
pregnant women
gptkbp:patent gptkb:Emory_University
gptkb:Merck_&_Co.
gptkb:Ridgeback_Biotherapeutics
gptkbp:pregnancyCategory not recommended
gptkbp:prescribes adults with COVID-19
gptkbp:prescriptionStatus prescription only
gptkbp:prodrugOf gptkb:N4-hydroxycytidine
gptkbp:riskFactor potential mutagenicity
gptkbp:routeOfAdministration oral
gptkbp:sideEffect nausea
diarrhea
dizziness
headache
gptkbp:storage room temperature
gptkbp:synonym gptkb:EIDD-2801
gptkb:MK-4482
NHC prodrug
gptkbp:target gptkb:COVID-19
gptkbp:usedFor gptkb:COVID-19
gptkbp:WHOModelListOfEssentialMedicines no
gptkbp:bfsParent gptkb:默沙东
gptkbp:bfsLayer 5